As the biotech world awaits the announcement of Merck’s anticipated buyout of Seagen, an arbitrator came down on the side of Daiichi Sankyo in a patent battle against the Seattle-based biotech.
https://www.pharmalive.com/wp-content/uploads/2022/08/BioSpacescales8-15-2022.jpg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-08-15 10:15:562022-08-15 10:15:56Seagen loses patent battle against Daiichi Sankyo as Merck waits in the wings
